Ч.Баттогтох
Loading...
Товч нэр
Ч.Баттогтох
Бүтэн нэр
Чимэддорж Баттогтох
Латин нэр
Chimeddorj Battogtokh
Албан тушаал
Захирал
Гэрээт багш
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
6 results
Now showing 1 - 6 of 6
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genealogical Identification and Short Tandem Repeat-Based Verification of Suspected Consanguinity in Mongolian Families(Informa UK Limited, 2026); ; ;Baatar, Buyandelger; PURPOSE: The prevalence of consanguineous marriages remains high in several regions worldwide, particularly the Middle East and South Asia, with a reported rate of 58%. However, the prevalence and genetic characteristics of consanguineous marriages in Mongolia are not well studied. This study aimed to estimate the frequency of consanguineous marriages in selected Mongolian populations, using genealogical and short tandem repeat (STR) analyses. PATIENTS AND METHODS: This cross-sectional study was conducted at the Institute of Biomedicine at the Mongolian National University of Medical Sciences. A total of 574 individuals from 185 families across 43 soums in three provinces (X1, X2, and X3) were included. Genealogical analysis was used to construct pedigree-based consanguinity profiles, and STR analysis was performed to validate biological relatedness in selected families. RESULTS: Seventeen families were consanguineous, with a mean inbreeding coefficient of 0.089 ± 0.136, whereas 42 families were classified as suspected consanguinity. Among the confirmed cases, seven families with complete biological samples were further analyzed using STR markers, of which five showed molecular evidence of consanguinity (probabilities, 76.18-98.84%). The STR analysis of 29 families classified as suspected or non-consanguineous identified 13 families as non-consanguineous and 10 families showing possible or indeterminate relatedness. Notably, six families initially classified as suspected or non-consanguineous demonstrated molecular evidence of consanguinity (probabilities, 70.75-99.85%). Genetic diversity analysis revealed reduced heterozygosity in offspring from consanguineous families (expected heterozygosity [HE] = 0.7580, observed heterozygosity[HO] = 0.7045) compared with offspring from non-consanguineous families (HE = 0.7858, HO = 0.8110), with a significant reduction in HO (p = 0.0009). CONCLUSION: This study demonstrates the value of integrating genealogical and STR-based molecular approaches for the assessment of consanguinity in Mongolia. Molecular analyses identified consanguineous relationships that were not evident from pedigree information alone and revealed reduced genetic diversity among offspring from consanguineous families. These findings provide important baseline data for understanding the genetic consequences of consanguinity in the Mongolian population and support the need for large scale epidemiological and genetic investigation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Newborn screening and biobanking for preventable genetic disorders in Mongolia: A developing country perspective(Elsevier BV, 2026-12); ; ; ; Newborn screening (NBS) is an important public health program, yet its implementation is highly uneven globally, with developing countries like Mongolia facing significant resource and infrastructure limitations that hinder early detection of preventable genetic disorders. Meanwhile, induced pluripotent stem cell (iPSC) technology, leveraged through biobanking, offers a powerful platform for disease modeling, drug discovery, and regenerative medicine, though its advanced applications are primarily concentrated in wealthier nations. We review the current status of NBS in Mongolia and argue for linking an expanded NBS program to an iPSC biobank. This link would improve diagnosis, create a foundation for Mongolian precision medicine, and strengthen local research capacity. We recognize the practical and ethical hurdles-funding, staffing, and data governance-and outline phased rollout, targeted training, and international partnerships as realistic next steps. Taken together, this approach could prevent avoidable disability in Mongolia while gradually building homegrown capability in genetic healthcare. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular epidemiology of SARS-CoV-2 in Mongolia, first experience with nanopore sequencing in lower- and middle-income countries setting(Wiley, 2023-12); ; ; ; Burged, NatsagdorjBACKGROUND: Coronavirus disease (COVID-19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two-stepped, nationally representative molecular epidemiologic study of SARS-CoV-2 in Mongolia for 2020 and 2021. METHODS: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant-specific real-time reverse transcription polymerase chain reaction (RT-PCR) test to detect SARS-CoV-2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at -70°C deep freezer, and tests were performed on samples with cycle threshold <30. RESULTS: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia. CONCLUSIONS: SARS-CoV-2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS-CoV-2 from Mongolia, where sequencing data is sparse.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 seroprevalence in Mongolia: Results from a national population survey(Elsevier BV, 2021-12); ; ;Le, Linh-Vi; BACKGROUND: With the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020, Mongolia implemented rapid emergency measures and did not report local transmission until November 2020. We conducted a national seroprevalence survey to monitor the burden of SARS-CoV-2 in Mongolia in the months surrounding the first local transmission. METHODS: During October-December 2020, participants were randomly selected using age stratification and invited for interviews and blood samples at local primary health centres. We screened for total SARS-CoV-2 antibodies, followed by two-step quantitative SARS-CoV-2 IgG serology tests for positive samples. Weighted and test-adjusted seroprevalences were estimated. We used chi-square, Fisher's exact and other tests to identify variables associated with seropositivity. FINDINGS: A total of 5000 subjects were enrolled. We detected SARS-CoV-2 IgG antibodies in 72 samples. Crude seroprevalence of SARS-CoV-2 antibodies was 1·44% (95%CI,1·21-1·67). Population weighted and test-adjusted seroprevalences were 1·36% (95%CI,1·11-1·63) and 1·45% (95%CI,1·11-1·63), respectively. Age, sex, geographical, and occupational factors were not associated with seropositivity (p>0·05). Symptoms and signs within past 3 months and seropositivity were not associated at the time of the survey (p>0·05). INTERPRETATION: SARS-CoV-2 seroprevalence in Mongolia was low in the first year of the pandemic potentially due to strong public health measures, including border restrictions, educational facilities closure, earlier adoption of mask-wearing and others. Our findings suggest large-scale community transmission could not have occurred up to November 2020 in Mongolia. Additional serosurveys are needed to monitor the local pandemic dynamic and estimate how far from herd immunity Mongolia will be following-up with vaccination programme in 2021 and 2022. FUNDING: World Health Organisation, WHO UNITY Studies initiative, with funding by the COVID-19 Solidarity Response Fund and the German Federal Ministry of Health (BMG) COVID-19 Research and development. TRANSLATION: Cyrillic and Traditional Mongolian translation of abstract is available on appendix section.Scopus© Citations 14 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia(2026-10); ; ;Kashiwakura, Yuji; Adeno-associated virus (AAV) vector-mediated gene therapy for hemophilia offers the potential for sustained therapeutic benefit after a single administration and is particularly attractive in regions with limited access to standard therapies. However, the prevalence of anti-AAV neutralizing antibodies (NAbs), which can impair therapeutic efficacy, varies geographically and remains poorly characterized in Mongolia. Here, we evaluated the seroprevalence of NAbs against clinically relevant AAV serotypes in Mongolia. NAbs against AAV3B, AAV5, and AAV8 were assessed in serum samples from 23 healthy volunteers and 52 people with hemophilia (PwH) using a validated cell-based transduction inhibition assay. A high seroprevalence of anti-AAV NAbs was observed across all three serotypes in both healthy volunteers (69.6%-87.0%) and PwH (78.9%-84.6%), with no significant differences between groups. NAbs were detected across all age groups, including early childhood, and frequently exhibited neutralization against multiple AAV serotypes, which was associated with higher NAb titers. Taken together, anti-AAV NAbs are highly prevalent and acquired early in life in the Mongolian population, with multiserotype neutralization patterns. These findings identify a substantial population-specific barrier to AAV-mediated gene therapy and highlight the need for alternative therapeutic strategies beyond AAV-based platforms to overcome immunological constraints in this setting. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study(Elsevier BV, 2023-04); ;Bailie, Christopher R; ;Price, David JBACKGROUND: The COVID-19 pandemic has global impacts but is relatively understudied in developing countries. Mongolia, a lower-middle-income country, instituted strict control measures in early 2020 and avoided widespread transmission until vaccines became available in February, 2021. Mongolia achieved its 60% vaccination coverage goal by July 2021. We investigated the distribution and determinants of SARS-CoV-2 seroprevalence in Mongolia over 2020 and 2021. METHODS: We performed a longitudinal seroepidemiologic study aligned with WHO's Unity Studies protocols. We collected data from a panel of 5000 individuals in four rounds between October 2020 and December 2021. We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling. We tested serum for the presence of total antibodies against SARS-CoV-2 receptor-binding domain, and levels of anti-SARS-CoV-2 spike IgG and neutralising antibodies. We linked participant data with national mortality, COVID-19 case, and vaccination registries. We estimated population seroprevalence and vaccine uptake, as well as unvaccinated population prior-infection prevalence. FINDINGS: At the final round in late 2021, 82% (n = 4088) of participants completed follow-up. Estimated seroprevalence increased from 1.5% (95% CI: 1.2-2.0), to 82.3% (95% CI: 79.5-84.8) between late-2020 and late-2021. At the final round an estimated 62.4% (95% CI: 60.2-64.5) of the population were vaccinated, and of the unvaccinated population 64.5% (95% CI: 59.7-69.0) had been infected. Cumulative case ascertainment in the unvaccinated was 22.8% (95% CI: 19.1%-26.9%) and the overall infection-fatality ratio was 0.100% (95% CI: 0.088-0.124). Health workers had higher odds for being COVID-19 confirmed cases at all rounds. Males (1.72 (95% CI: 1.33-2.22)) and adults aged 20 and above (12.70 (95% CI: 8.14-20.26)) had higher odds for seroconverting by mid-2021. Among the seropositive, 87.1% (95% CI: 82.3%-90.8%) had SARS-CoV-2 neutralising antibodies by late 2021. INTERPRETATION: Our study enabled tracking of SARS-CoV-2 serological markers in the Mongolian population over one year. We found low SARS-CoV-2 seroprevalence in 2020 and early 2021, with seropositivity increasing over a 3-month interval in 2021 due to vaccine roll out and rapid infection of most of the unvaccinated population. Despite high seroprevalence in Mongolia amongst both vaccinated and unvaccinated individuals by end-2021, the SARS-CoV-2 Omicron immune escape variant caused a substantial epidemic. FUNDING: World Health Organization, WHO UNITY Studies initiative, with funding by the COVID-19 Solidarity Response Fund and the German Federal Ministry of Health (BMG) COVID-19 Research and development. The Ministry of Health, Mongolia partially funded this study.Scopus© Citations 7
